Mayne Pharma Aspires To Specialisation
Mayne Pharma aspires to have more than 60% of its FY24 revenue from US specialty products, although significant challenges in generics are likely to beset the business in the interim.
Read MoreTag: MYX
MYX – UBS rates the stock as Neutral
The company has indicated that gross revenue for the first four months of FY20 is down -16%. Key products in generics, liothyronine, and dofetilide, continue to lose share to competitors. Specialty revenue was broadly flat. Contract services revenue increased by 16%.
Read MoreRed Alert: 7-Eleven Closes On Metcash, Gentrack Off Track, Mayne Pharma Pain
Bad news Friday, at least for three ASX-listed companies. 7-Eleven’s decision to walk away on a supply deal has left Metcash shares deep in the red while Gentrack and Mayne Pharma have disappointed investors with new profit warnings.
Read MoreMYX – Credit Suisse rates the stock as Neutral
The launch of new generic drugs fentora and efudex has been strong, with 40% and 30% market share respectively. Yet Credit Suisse suspects this has not been enough to offset competition and earnings decline in the first half.
Read MoreMYX – Credit Suisse rates the stock as Neutral
The company has signed an exclusive licence and supply agreement to commercialise a combined oral contraceptive in the US for total consideration of US$295m. The product is to be launched in the second half of FY21, subject to FDA approval.
Read MoreMayne Pharma Rockets On US Contraceptive Deal
Mayne Pharma shares jumped nearly 19% yesterday a near five-month high after the company revealed an exclusive long-term deal to sell a new contraceptive drug in the USA.
Read MoreEarnings Shorts: Mayne Pharma, Costa Group
A big loss for generics pharmaceuticals maker Mayne Pharma in 2018-19 surprisingly produced a big gain, meanwhile listed horticulture producer and distributor Costa Group has reported a 15% drop in statutory interim profit.
Read MoreMYX – Credit Suisse rates the stock as Neutral
Credit Suisse reviews script volume trends for the company’s key generic and specialty brands. With limited improvement in the final six weeks of FY19 the broker envisages downside risk to consensus forecasts.
Read MoreMYX – Credit Suisse rates the stock as Downgrade to Neutral from Outperform
The company has announced a significant deterioration in the performance of its generic products since the first half results because of increased competition and US$4m in one-off adverse items. The high-margin specialty brands revenue is also weaker than expected.
Read MoreGeneric Medicine Margins Pressure Mayne Pharma
A rather severe confession time yesterday from generic drug group, Mayne Pharma with a warning of a big slide in revenue and profit and a possible write-down of asset values.
Read MoreMYX – UBS rates the stock as Neutral
Mayne Pharma’s result was a big improvement on a weak previous period but was currency-assisted and disappointed nonetheless. Specialty brands stood out in revenue terms, the broker notes, but costs were elevated for various reasons.
Read More‘Soft’ Mayne Pharma Disappoints
Generic drugs group, Mayne Pharma saw its shares dip yesterday in the wake of yet another poor trading update.
Read MoreMayne Pharma Trading Update Falls Short
Generic drug group, Mayne Pharma disappointed investors yesterday with the release of preliminary results for 2016-17 underwhelming investors.and sending the shares down nearly 10% to 81 cents.
Read MoreMYX – UBS rates the stock as Buy
Mayne’s investor day highlighted a plan to triple sales by 2021 through new product launches and M&A, which might have been exciting had the company not also revealed 10-15% quarterly price deflation in the generic portfolio acquired from Teva. Buyer consolidation was blamed.
Read MoreMayne Pharma Faces Trump Headwinds
Mayne Pharma Group’s (MYX) share price fell more than 10% to $1.20 yesterday and for that you can partly blame President Donald Trump and his erratic talk about controlling drug prices.
Read MoreStrong New Drug Sales Lift Mayne Pharma
Manufacturer and distributor of pharmaceuticals, Mayne Pharma ((MYX)), is continuing its transformation and now has a portfolio of branded and generic medicines which have elevated it to a substantial player globally. The company has more development capability and directly distributes into the US. The market for generic medicines in the US is estimated to be at a US$60bn, and growing.
Read MoreMayne Pharma Delivers
Drug maker Mayne Pharma (MYX) is one of those rare stocks where investors expect much more from it in the coming year, than they saw in the year to June 30.
Read MoreMayne Pharma confirms over half a billion successful institutional placement, shares surged 28%
Mayne Pharma shares surged 28% yesterday after the company confirmed it had raised over half a billion in an institutional placement at $1.50 a share and rights issue as part of its dramatic move into the competitive US generic drugs market.
Read MoreMYX – UBS rates the stock as Buy
Mayne Pharma ‘ FY15 result came in in line with the broker after the turmoil of the first half, when the US Doryx distributor transitioned ownership, gave way to full Doryx margin reestablishment in the second half after Mayne acquired the Doryx brand.
Read More